FABULINUS

This app is intended for use by participants in the FABULINUS study and requires an invitation and activation code from the study site to register. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy. This study has been reviewed and approved by the appropriate regulatory body, e.g. Institutional Review Board (IRB) or Independent Ethics Committee (IEC).

Key App Features:

- Patient Onboarding – complete study app registration and education

- Activities – on-demand study tasks and assessments are sent from the site to the participant

- Dashboard – review overall progress in the study and current activities

- Resources – view study information in the Learn section of the app

- Profile – manage account details and app settings

- Notifications – receive in-app reminders

- Telehealth – conduct scheduled virtual visits with your study site

About THREAD:

THREAD’s® purpose is to leverage its clinical research platform to enable studies for everyone, everywhere. The company’s uniquely combined clinical research technology and consulting services help life science organizations to design, operate, and scale next-generation research studies and electronic clinical outcome assessments (eCOA) programs for participants, sites, and study teams. Through its comprehensive platform and scientific expertise, THREAD empowers studies to be accessible, efficient, and centered on the patient.